摘要
目的观察当飞利肝宁胶囊联合二甲双胍治疗非酒精性脂肪性肝病(NAFLD)的临床疗效。方法选取2010年2月-2012年12月医院收治的NAFLD患者120例,接受当飞利肝宁胶囊联合二甲双胍治疗,观察患者治疗前后血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、三酰甘油(TG)、总胆固醇(CHO)、超敏C反应蛋白(hs-CRP)变化情况,超声图像变化及药物不良反应。结果治疗后临床症状较治疗前明显改善者109例,有效率90.83%;治疗后超声影像表现较治疗前明显好转;ALT、AST、TG、CHO、hs-CRP较治疗前显著改善,差异有统计学意义(P<0.05)。所有患者治疗期间均未出现不良反应。结论当飞利肝宁联合二甲双胍治疗NAFLD患者,血脂、肝功能、肝纤维化、超声等指标均有明显改善,疗效显著。
Objective To investigate the different efficacy of antiviral treatment in patients with different stages of acute on-chronic hepatitis B liver failure. Methods A total of 118 patients with acute-on-chronic hepatitis B liver failure,were classified to 60 cases of early stage,42 cases of medium stage and 12 cases of later stage. Every stage was divided into two groups,one was treated with antiviral therapy（ LAM or ETV） and routine supportive therapy,artificial liver support system while the control group was treated with supportive therapy and artificial liver support system only. To observe and compare the short-term（ 12weeks） efficacy of antiviral therapy were difference among three stages. Results There was significant difference in the survival rate among the patients with different stages of acute-on-chronic hepatitis B liver failure（ P〈0. 05）. As the liver function got worse,there was lower survival rate of patients. There was no significant difference in the survival rate between the antiviral therapy group and the control group of later stage（ P〈0. 05）. On the contrary the survival rate of patients in the antiviral therapy group was higher than that in control group of the early and medium stage（ P〈0. 05）. Conclusion Antiviral therapy can significantly improve survival rate of patients of earl and medium stage acute-on-chronic hepatitis B liver failure. Otherwise antiviral therapy have no effect on survival rate of patients of later stage.
出处
《临床合理用药杂志》
2015年第17期14-15,共2页
Chinese Journal of Clinical Rational Drug Use
